Table 1.
Patients’ characteristics.
| Characteristics | Number of patients (n = 49) | % |
|---|---|---|
| Age (years) | Median 48 (range, 30–69) | |
| Sex | ||
| Female | 13 | 26.5 |
| Male | 36 | 73.5 |
| ECOG performance status | ||
| 0 | 10 | 20.4 |
| 1 | 25 | 51.0 |
| 2 | 14 | 28.6 |
| Tumor-involved site | ||
| Nasopharyngeal | 5 | 10.2 |
| Lymph node | 12 | 24.5 |
| Lung | 27 | 55.1 |
| Liver | 14 | 28.6 |
| Bone | 7 | 14.3 |
| Number of involved sites | ||
| 1 | 28 | 57.1 |
| 2 | 14 | 28.6 |
| 3 | 7 | 14.3 |
| Initial received platinum-based chemotherapy for recurrence or metastases | ||
| Cisplatin + 5-FU | 6 | 12.2 |
| Cisplatin + gemcitabine | 18 | 36.7 |
| Cisplatin + docetaxel | 17 | 34.7 |
| Cisplatin + paclitaxel | 11 | 22.4 |
| Carboplatin + paclitaxel | 12 | 24.5 |
| Number of chemotherapy regimens received | ||
| One | 16 | 32.7 |
| Two | 23 | 46.9 |
| ⩾Three | 10 | 20.4 |
5-FU, 5-fluorouracil; ECOG, Eastern Cooperative Oncology Group.